Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote ()	4/21/1999 4:45:00 PM
From: scaram(o)uche	Read Replies (1) of 4974

Wednesday April 21, 4:29 pm Eastern Time Company Press Release SOURCE: MedImmune, Inc. MedImmune First Quarter Product Sales Nearly Triple - Synagis(TM) Launch Reaches $226 Million in First Season - GAITHERSBURG, Md., April 21 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI - news) today reported net sales of Synagis(TM) (palivizumab) in first quarter 1999 of $116.2 million and total product sales of $127.0 million, nearly triple first quarter 1998. Net sales of Synagis(TM) for the 1998/1999 respiratory syncytial virus (RSV) season have been $225.9 million through March 31, 1999. Earnings per share more than doubled to $0.45 per share, diluted and fully taxed, on 65.5 million shares in first quarter 1999 from $0.21 per share, diluted but untaxed, on 63.2 million shares in first quarter 1998. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next